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ABSTRACT: The N-chloroformylimidazolidinone derivative of enantiopure L-alanine was deprotonated to form an enolate 
and functionalized with a series of allylic halides. Treatment of the resulting carbamoyl chlorides with potassium iodide led 
to cyclisation of the allylic substituent onto the carbonyl group in an intramolecular aliphatic Friedel Crafts-type acylation 
that corresponds to an aliphatic Bischler-Napieralski reaction. The product 3,4-dihydropyridinones were amenable to further 
functionalization, and finally hydrolysis, to deliver a series of enantioenriched pipecolic acid derivatives.  
The dihydropyridin-2-one scaffold and its derivatives are 
found embedded in a number of naturally occurring alka-
loids and constitutes the core of many other biologically rel-
evant compounds. Examples include the small molecule di-
rect thrombin inhibitor argatroban, which acts as an antico-
agulant.1,2 Dutasteride is a 5α-reductase inhibitor, approved 
for the treatment of enlarged prostate.3,4 Setrobuvir is an ex-
perimental drug candidate (Phase II) which is used along-
side interferon for the treatment of hepatitis C patients.5 
Piperlongumine belongs to the Piperaceae family of natural 
products, which are widely known for their anti-cancer 
properties (Figure 1).6,7 
 
Figure 1. Bioactive 4,5-dihydropyridin-2-one derivatives 
Recently reported connective syntheses of the dihydro-
pyridinone ring system have involved intramolecular attack 
of enamines on Michael acceptors8 or epoxides, 9 cycloaddi-
tions of imines,10 and carbamoylation of alkenes.11  We re-
cently reported a synthesis of the benzo-fused analogues of 
3,4-dihydropyridin-2-ones, namely 3,4-dihydroisoquino-
linones, by an unusual version of the Bischler-Napieralski 
cyclisation entailing the intramolecular KI-promoted 
Friedel-Crafts acylation of N-chloroformylimidazolidinones 
(Scheme 1).12 The starting materials for these reactions, im-
idazolidinone-derived carbamoyl chlorides carrying a 3-
benzyl substituent, were formed diastereoselectively either 
directly from aromatic amino acids (for example, L-Phe)12 
or by stereoselective benzylation13 of the stable enolates14 
of their N-chloroformyl substituted precursors.15 
 
Scheme 1. Dihydroisoquinolones by cyclization of amino 
acid-derived N-chloroformylimidazolidones 
We now show that 3,4-dihydropyridin-2-ones may likewise 
be formed by intramolecular Friedel-Crafts reaction, from 






























































































version11 of the Bischler-Napieralski reaction16,17 forms ver-
satile products that may be used as precursors to function-
alized saturated or unsaturated pipecolic acid derivatives 
bearing a quaternary centre  to nitrogen (Scheme 1).  
The work started with the enantiopure N-chloroformylim-
idazolidinone derivative 1a, formed as a single trans dia-
stereoisomer12 from L-Ala. The potassium enolate of this 
heterocycle, formed by treatment with KHMDS, is stable 
enough to be trapped with allylic electrophiles at –78 °C.14 
Better yields were obtained by shortening the interval be-
tween the addition of the base and the electrophile (see SI 
for optimization table), and the optimal conditions involved 
treating N-chloroformylimidazolidinone 1a with KHMDS 
(1.2 eq) and stirring for 2 min before adding the electro-
phile, which was left to react for 2 h at –78 °C. 
The enolate reacted successfully with allyl bromides bear-
ing a variety of functional groups and substitution patterns 
(i.e. where R1 or R2 ≠ H). Using these optimized reaction con-
ditions we synthesized a range of enantiopure N-chlo-
roformylimidazolidinones 2a-2k carrying a variety of dif-
ferently substituted allyl substituents (Scheme 2) in good to 
excellent yields. As observed previously, the addition of the 
electrophile was fully diastereoselective (none of the cis-al-
lylated diastereomer was observed by 1H NMR), with nOe 
confirming that the electrophile approaches anti to the 
bulky tert-butyl group.  
 
Scheme 2. Diastereoselective allylation 
Intramolecular electrophilic attack of the N-chloroformyl 
group onto the alkene was induced by treatment with KI, 
which we assume generates a transient acyl iodide 
intermediate.18  Using 3-allyl N-chloroformylimidazoli-
dinone 2a as a model substrate (Table 1) we found that cy-
clization was complete after 2 h in the presence of 1.1 equiv 
2,6-lutidine (entry 1), but gave a mixture of alkene regioiso-
mers: the conjugated product 3a and unconjugated product 
4a formed in a 41:59 ratio. The products were separated by 
flash chromatography, and their structures confirmed by X-
ray crystallography (Figure 2).19 Alternative activation of 
the chloroformyl group by complexation to AlCl3 gave a sin-
gle diastereoisomer of the chlorinated product 5 in signifi-
cant amounts (entry 2). 
Table 1. Optimization of the cyclocarbonylation 
 








1 2,6-Lutidine (1.1) 41:59 39 50 
2 [AlCl3]d – 46 22e 
3 DBU (1.1) 63:37 34 21 
4 DBU (3.0) 77:23 19 19 
5a 2,6-Lutidine (1.1) 
then DBU (5) 
85:15 43  
- 
6b 2,6-Lutidine (1.1) 
then DBU (5) 
85:15 39 - 
 
7c 2,6-Lutidine (1.1) 
then DBU (3) 
- 45f + 43g 
 
50f 
aTreated with DBU (2 h, 150 °C) before work-up. bTreated 
with DBU (2 h, 150 °C) after work-up.  cProducts separated  
and isolated; 4a then treated with DBU (2 h, 150 °C). dNo 
base used; AlCl3 in CH2Cl2 used instead of KI. eYield of 5. 
fYield formed in initial cyclization. gFurther material iso-
lated after isomerization from 4a. 
 






































































































































2a 3a 4a 5
 
 
Looking to improve the isolated yield of the more useful 
conjugated product 3a, we explored the reaction in the 
presence of alternative bases. Donohoe et al. reported the 
use of DBU to isomerize an unconjugated double bond into 
conjugation in a related heterocycle.20 Using DBU in place of 
2,6-lutidine (entries 3 and 4) improved the proportion of 3a 
in the crude material to 63-77%, but isolated yields were 
moderate.  More satisfactory was a stepwise protocol (entry 
5) in which the starting material was treated with KI and 
2,6-lutidine to induce cyclization, followed by DBU to effect 
isomerization to 3a, either with or without work-up be-
tween the steps (entries 6, 7). This procedure gave solely 
3a, but still in relatively poor yield. The optimal procedure 
turned out to be the separation of 4a from 3a, followed by 
isomerization of the isolated 4a to 3a in a separate step, 
which gave an overall combined yield of 88% 3a (entry 7). 
The scope of the intramolecular aliphatic Friedel Crafts acy-
ation, which amounts to an aliphatic equivalent of the Bis-
chler-Napieralski cyclization, was explored by cyclization of 
imidazolidinones 2b-2h. These substrates, bearing 2-sub-
stituted allyl groups, cyclized to give chromatographically 
separable mixtures of regioisomers 3 and 4 in ratios com-
parable to those seen with 2a. As before, treatment with 
DBU returned good yields of the conjugated products 3b-3g 
(Scheme 3). Imidazolidinone 2h, with a 2-methallyl substit-
uent, gave (in addition to 3h and 4h) a third regioisomer 6h 
containing an exocyclic double bond. 
 
Scheme 3. Scope of the cyclocarbonylation. aYield isolated 
after step a. bCombined isolated yield from step a and step 
b. 
Substrates in which the allyl group was substituted at the 
terminal position also gave a more diverse range of out-
comes (Scheme 4). Cinnamyl-substituted 2i (Scheme 4a), 
underwent cyclisation to form a five-membered ring, 
presumably as a result of the more stable benzylic cation 
that forms. Two alkene stereoisomers E- and Z-7i were 
formed, their geometry being assigned from the X-ray crys-
tal structure of the E isomer (Figure 2c).  
The crotyl substituent of 2j gave, under the same condi-
tions, both 6- (3j) and 5-membered cyclized products 
(Scheme 4b), with the 5-membered products being gener-
ated as a mixture of double bond isomers 7j and 8j. 
Attempts were made to bias this cyclization towards the 
six-membered ring 3 by incorporation of a silyl directing 
group in precursor 2k. 6-ring selectivity improved as a re-
sult, with 3a becoming the major product, but surprisingly 
5-ring 7k was still formed in significant amounts (Scheme 
4c).  
 
Scheme 4. Cyclization of terminally substituted allyl sub-
stituents. 
 
The imidazolinone-fused 3,4-dihydropyridin-3-ones 3, 4 
and 6 present a reactive electrophilic alkene within a highly 
stereodefined environment, and thus offer many possibili-
ties for application in enantioselective synthesis of pyridi-
none and pipecolic acid derivatives through further func-
tionalization.21 A number of such transformations are illus-
trated in Scheme 5. 
+
 DBU (3 equiv), 2 hStep b
Step a
 2,6-lutidine (1.1 equiv)
KI (1.1 equiv)
MeCN, mw, 150 ºC































































































































































Scheme 5. Functionalization of the dihydropyridinone 
scaffold. aConditions (a); bConditions (b). In addition, 18% 
dithioester formed (see SI). 
Conjugate addition of thioacetate to the unsaturated alkene 
3a gave diastereoselectively the thioesters 9a and 9b with 
the major diastereoisomer depending on the conditions 
used. Dihydroxylation of 3a, 4h or 6h gave the diols 10 
highly diastereoselectively by functionalization of the endo 
face of the bicycle, anti to the ring junction methyl group and 
the tert-butyl substituent. Hydrogenation of 3a, 3c and 3h 
provides pipecolic acid derivatives 11. Further chemoselec-
tive reduction of 11a gave pipecolic acid derivative 12. Re-
moval of the directing imidazolidinone motif to reveal the 
parent ring systems was achieved by acid-catalyzed hydrol-
ysis to the products 13a-13e (Scheme 6), allowing the for-
mation of a range of enantiopure lactams carrying fully sub-
stituted stereogenic centres. 
 
 
Scheme 6. Hydrolysis to give pipecolic acid derivatives. 
Overall, the method makes further use of the versatile 
amino-acid derived enantiopure N-chloroformylimidazoli-
dinones – both their stability towards base and enolate gen-
eration, and their intramolecular electrophilicity towards 
carbon nucleophiles on activation by iodide. By providing a 
route to enantiopure 3,4-dihydropyridinones, it enables a 
useful and potentially highly versatile route to pharmaceu-
tically relevant substituted derivatives of pipecolic acid. 
Supporting Information 
The supporting information contains full experimental details 
and spectroscopic characterization of all new compounds. The 
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